Astute Medical Logo
Innovative biomarkers.  Smarter healthcare.

Proven Leadership

The Astute Board of Directors consists of individuals with proven leadership skills
which allow for successful innovation and commercialization.

One of few life science tools companies focused on prognostic biomarker validation, Astute is led by CEO Hibberd. McPherson leads scientific decisions involving prognostic biomarker validation for Astute Medical. One of few life science tools companies focused on prognostic biomarker validation, Astute is led by CEO Hibberd. One of few life science tools companies focused on prognostic biomarker validation, Astute is led by CEO Hibberd. One of few life science tools companies focused on prognostic biomarker validation, Astute is led by CEO Hibberd. One of few life science tools companies focused on prognostic biomarker validation, Astute is led by CEO Hibberd. One of few life science tools companies focused on prognostic biomarker validation, Astute is led by CEO Hibberd. One of few life science tools companies focused on prognostic biomarker validation, Astute is led by CEO Hibberd.
The Astute Medical Board of Directors Click photos to see a biography
Christopher R. Hibberd | Chief Executive Officer, Co-Founder
Paul H. McPherson, PhD | Chief Scientific Officer, Co-Founder
James C. Blair | Board of Directors
Kim D. Blickenstaff | Board of Directors
Kenneth F. Buechler, Ph.D. | Board of Directors
Frederick J. Dotzler | Board of Directors
David L. Douglass | Board of Directors
Jim Scopa, JD, MBA | Board of Directors
©2017 Astute Medical, Inc. Astute Medical®, the AM logo, Astute140®NephroCheck®, the NephroCheck® logo, and AKIRisk® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/us/about/intellectualproperty. PN 0228 Rev D 2016/08/22